39.82
1.27 (3.29%)
| Previous Close | 38.55 |
| Open | 39.04 |
| Volume | 242,260 |
| Avg. Volume (3M) | 461,298 |
| Market Cap | 811,093,568 |
| Price / Sales | 107.42 |
| Price / Book | 2.05 |
| 52 Weeks Range | |
| Earnings Date | 11 Aug 2025 - 15 Aug 2025 |
| Operating Margin (TTM) | -2,868.84% |
| Diluted EPS (TTM) | -10.66 |
| Quarterly Revenue Growth (YOY) | 1,349.10% |
| Total Debt/Equity (MRQ) | 0.24% |
| Current Ratio (MRQ) | 8.44 |
| Operating Cash Flow (TTM) | -163.91 M |
| Levered Free Cash Flow (TTM) | -90.04 M |
| Return on Assets (TTM) | -39.95% |
| Return on Equity (TTM) | -63.56% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bearish | Bearish |
| Biotechnology (Global) | Bearish | Bearish | |
| Stock | Praxis Precision Medicines, Inc | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | -0.5 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 2.0 |
| Average | 0.50 |
|
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 0.16% |
| % Held by Institutions | 122.04% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 105.00 (HC Wainwright & Co., 163.69%) | Buy |
| Median | 80.00 (100.90%) | |
| Low | 28.00 (Wedbush, -29.68%) | Sell |
| Average | 78.00 (95.88%) | |
| Total | 4 Buy, 1 Sell | |
| Avg. Price @ Call | 39.99 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Needham | 12 Jun 2025 | 80.00 (100.90%) | Buy | 45.03 |
| 05 May 2025 | 80.00 (100.90%) | Buy | 38.96 | |
| Oppenheimer | 02 Jun 2025 | 97.00 (143.60%) | Buy | 39.82 |
| Chardan Capital | 07 May 2025 | 80.00 (100.90%) | Buy | 38.09 |
| Wedbush | 05 May 2025 | 28.00 (-29.68%) | Sell | 38.96 |
| HC Wainwright & Co. | 01 May 2025 | 105.00 (163.69%) | Buy | 38.06 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |